References
- 1. American College of Obstetricians and Gynecologists. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’ task force on hypertension in pregnancy. Obstetrics and gynecology. 2013; 122(5): 1122-1130.
- 2. Eiland E, Nzerue C, Faulkner M. Preeclampsia 2012. J Pregnancy. 2012; 586-578.
- 3. Prakash J, Ganiger VC. Acute Kidney Injury in Pregnancy-specific Disorders. Indian J Nephrol. 2017; 27(4):258-70.
- 4. Sand JMB, Genovese F, Gudmann NS, Karsdal MA. Type IV collagen. – In: Biochemistry of Collagens, Laminins and Elastin, 2nd ed.; Karsdal, MA, Ed.; Elsevier: Amsterdam, The Netherlands, 2019; Chapter 4: pp. 37-49.
- 5. Li Na, Ghosh G, Gudmundsson S. Uterine artery Doppler in high-risk pregnancies at 23-24 weeks of gestation is of value in predicting adverse outcome of pregnancy and select cases for more intense surveillance. Acta Obstet Gynecol Scand. 2014; 93: 1276-81.
- 6. Mansell JP, Bailey AJ. Collagen Metabolism. – In: Encyclopedia of Endocrine Diseases; Martini L, Ed.; Elsevier: Amsterdam, The Netherlands, 2004: pp. 520-529.
- 7. Hudson BG, Tryggvason K, Sundaramoorthy M, Neilson EG. Alport’s syndrome, Goodpasture’s syndrome, and type IV collagen. N Engl J Med. 2003; 348: 2543-2556.
- 8. Tryggvason L, Patrakka J. Alport’s Disease and Thin Basement Membrane Nephropathy. – In: Genetic Diseases of the Kidney; Lifton RP, Somlo S, Giebisch GH, Eds.; Elsevier: Amsterdam, The Netherlands, 2009; Chapter 4: pp. 77-96.
- 9. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: Structure function and biochemistry. Circ Res. 2003; 92: 827-839.
- 10. Amaral LM, Wallace K, Owens M, Lamarca B. Pathophysiology and current clinical management of preeclampsia. Curr Hypertens Rep. 2017; 19: 61.
- 11. Lees C. First-trimester screening for pre-eclampsia and fetal growth restriction: a test seeking both a treatment and an optimal timing. Ultrasound Obstet Gynecol. 2010; 35(6): 647-9.
- 12. Cnossen JS, Morris RK, terRiet G, et al. Use of uterine artery Doppler ultrasonography to predict pre-eclampsia and intrauterine growth restriction: a systematic review and bivariable meta-analysis. CMAJ. 2008; 178(6): 701-11.
- 13. Harrington K, Fayyad A, Thakur V, Aquilina J. The value of uterine artery Doppler in the prediction of uteroplacental complications in multiparous women. Ultrasound in Obstetrics and Gynaecology 2004; 23: 50-55.
- 14. European Society of Cardiology (ESC) Guideline for the management of cardiovascular diseases during pregnancy. Eur Heart J 2018; 39(34): 3165-3241.
- 15. ISUOG Practice Guidelines: use of Doppler ultrasonography in obstetrics. Ultrasound Obstet Gynecol. 2013; 41: 233-239.
- 16. Li W, Mata KM, Mazzuca MQ, Khalil RA. Altered matrix metalloproteinase- 2 and -9 expression/activity links placental ischemia and anti-angiogenic sFlt-1 to uteroplacental and vascular remodeling and collagen deposition in hypertensive pregnancy. Biochem Pharmacol. 2014; 89: 370-385.
- 17. Ren Z, Cui N, Zhu M, Khalil RA. Placental growth factor reverses decreased vascular and uteroplacental MMP-2 and MMP-9 and increased MMP-1 and MMP-7 and collagen types I and IV in hypertensive pregnancy. Am J Physiol Heart Circ Physiol. 2018; 315: H33-H47.
- 18. Dias-Junior CA, Chen J, Cui N. Angiogenic imbalance and diminished matrix metalloproteinase-2 and -9 underlie regional decreases in uteroplacental vascularization and feto-placental growth in hypertensive pregnancy. Biochem Pharmacol. 2017; 146: 101-116.
- 19. Laskowska M. Altered maternal serum matrix metalloproteinases MMP-2, MMP-3, MMP-9, and MMP-13 in severe earlyandlate-onset preeclampsia. BioMed Res Int. 2017; 1-9.
- 20. Myers JE, Merchant SJ, MacLeod M et al. MMP-2 levels areelevated in the plasma of women who subsequently develop preeclampsia. Hypertens Pregnancy 2005; 24: 103-115.
- 21. Palei AC, Sandrim VC, Amaral LM, et al. Association between matrix metalloproteinase (MMP)-2 polymorphisms and MMP-2 levels in hypertensive disorders of pregnancy. Exp Mol Pathol. 2012; 92: 217-221.
- 22. Montagnana M, Lippi G, Albiero A, et al. Evaluation of metalloproteinases2 and 9 and their inhibitors in physiologic and pre-eclamptic pregnancy. J Clin Lab Anal. 2009; 23: 88-92.
- 23. Narumiya H, Zhang Y, Fernandez-Patron C et al. Matrix metalloproteinase-2 is elevated in the plasma of women with preeclampsia. Hypertens Pregnancy. 2001; 20: 185-194.
- 24. Popek EJ. Normal anatomy and histology of the placenta. In: SHLewis, EZ Perrin, editors. Pathology of the Placenta, secondedition. Philadelphia: Churchill Livingstone, 1999; 49-88.
- 25. Kelly BA, Bond BC, Poston L. Gestational profile of matrix metalloproteinases in rat uterine artery. Mol Hum Reprod. 2003; 9: 351-358.
- 26. Liotta LA, Steeg PS, Stetler-Stevenson WG. Cancer metastasisand angiogenesis: An imbalance of positive and negative regulation. Cell. 1991; 64: 327-336.
- 27. Palei AC, Sandrim VC, Cavalli RDC, Tanus-Santos JE. Comparative assessment of matrix metalloproteinase (MMP)-2 and MMP-9, and their inhibitors, tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2 in preeclampsia and gestational hypertension. Clin Biochem. 2008; 41: 875-880.
- 28. Fernandez-Patron C, Radomski MW, Davidge ST. Vascular matrix metalloproteinase-2 cleaves big endothelin-1 yielding a novel vasoconstrictor. Circ Res. 1999; 85(10): 906-911.
- 29. Donnelly R, Collinson DJ, Manning G. Hypertension, matrix metalloproteinases and target organ damage. J Hypertension 2003; 21: 1627-1630.